Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans by S. Diamond et al.
J Headache Pain (2007) 8:13–18
DOI 10.1007/s10194-007-0354-7
Sumatriptan 6 mg subcutaneous as an 
effective migraine treatment in patients 
with cutaneous allodynia who historically fail 
to respond to oral triptans





Abstract The objective of the study
was to assess the efficacy of 6 mg
subcutaneous (SC) sumatriptan to
treat migraine and the relationship
between response of migraine and
cutaneous allodynia in a population
of migraine patients who historical-
ly failed to respond to oral triptan
medications. This was an open-
label study consisting of patients
with migraines who historically
failed to respond to oral triptan
medications. Forty-three patients
were asked to treat three migraine
attacks with 6 mg SC sumatriptan.
The primary efficacy endpoint was
the percentage of patients achieving
relief of headache at 2 h. Ninety-
one percent of the patients respond-
ed to a single dose of SC sumatrip-
tan 6 mg. Fifty percent of all
patients were pain-free by 2 h and
over 30% had a 24-h sustained
pain-free response. When adminis-
tered within 90 min from the onset
of migraine (i.e., during the devel-
oping phase of cutaneous allody-
nia), SC 6 mg sumatriptan proved
to be effective despite the occur-
rence of allodynia in a group of
patients, who historically had failed
to respond to oral triptan medica-
tions. These findings suggest that
the window of opportunity to treat
allodynic patients with injectable
triptans may be longer (up to 2 h)
than with oral triptans (up to 1 h).
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Introduction
Since the initial introduction of triptans, selective sero-
tonin (5-hydroxy-tryptamine, 5-HT) 5-HT1B/1D receptor
agonists have become the treatment of choice for the relief
of moderate-to-severe migraine attacks [1]. The use of
triptans has been associated with reduction in both dis-
ability and productivity loss secondary to migraine [2].
The first triptan introduced in the USA was sumatriptan in
a 6-mg subcutaneous (SC) injection. There are currently
seven triptans available in the USA with several formula-
tions available for delivery including oral tablets, orally
disintegrating tablets, nasal sprays and SC injection [3].
Previous studies have demonstrated that 6-mg SC suma-
triptan has the highest response rate for any of the available
triptans. The US Headache Consortium Guidelines [4]
reviewed the results of placebo-controlled trials and reported
that the 14 trials of SC sumatriptan 6 mg compared to place-
bo demonstrate consistent superiority for both headache relief
and complete relief at the 1- and 2-h time points. Two other
trials compared SC and oral formulations of sumatriptan.
These trials demonstrated that SC sumatriptan was signifi-
cantly more effective than oral sumatriptan at both 2 and 4 h.
Response to triptans may depend on the duration [5, 6] and
severity of migraine attacks, but also the rapidity of achieving
therapeutic concentrations [7]. Improved response to triptan
medications may occur through several methods. One of these
would be to increase the dose of the oral triptan [8, 9].
Another approach would be to use a SC route of administra-
tion of the drug as is available for sumatriptan. This delivery
method and agent has the earliest therapeutic drug levels of
any triptan. In patients who are non-responders to oral triptan,
the use of a SC route of drug delivery can prove effective.
Clinical trials demonstrate that there are several other
factors influencing the efficacy of triptans. The development
of cutaneous allodynia (central sensitisation) is one of them.
The biology underlying central sensitisation, its develop-
ment and contribution [10] to the migraine process and subse-
quent impact on migraine treatment, has become one of the
foremost issues in headache research in the past several years.
Allodynia does not occur in all patients with migraine.
Burstein et al. has estimated that approximately 70% [11] of
migraine patients may develop cutaneous allodynia during
their attacks. The severity of the patient’s migraine attacks, the
patient’s age and the number of years that they have had their
migraines may be contributing factors to the development of
allodynia [11]. Burstein and Jakubowski have suggested that
in those who develop allodynia there may be a narrow win-
dow of opportunity [12] for the patient to be able to achieve
pain-free results with oral triptan treatment. Once the allody-
nia is established, and with this the process of central sensiti-
sation, then it is believed that the patient can only achieve res-
olution of the throbbing stage [13] of their pain and will not be
able to achieve pain-free status for that migraine attack.
Objectives
The objective of this study was to assess the efficacy and tol-
erability of 6 mg SC sumatriptan in the treatment of
migraine pain in a recidivist population of migraine patients
who historically failed to respond to oral triptan medications
for acute migraine treatment. Additionally, we attempted to
assess the relationship between response to treatment and
symptomatic cutaneous allodynia in this population.
Methods
This was an open-label study. Patients were selected from a popu-
lation consisting of those with migraine who historically had failed
to achieve relief from an oral triptan in at least 2 out of 3 attacks.
Subjects were screened for a history of migraine headache with or
without aura fulfilling the criteria of the International Headache
Society [14]. They were required to be in good health with no con-
comitant cardiovascular disease or other significant medical or psy-
chiatry illness that would affect their ability to make use of the
study medication. They were required to either not be using daily
preventive medications or to have a stable regimen of preventive
medications for at least one month prior to study enrollment. By
definition, the patients must have used triptans in the past and had
a history of having been unable to achieve relief from their heada-
che pain in at least two out of three attacks. They were required to
be naïve to the use of SC sumatriptan. Subjects underwent a brief
physical examination and were instructed in the use of the study
medication and the completion of their headache diaries. They were
provided with adequate medication to treat three headache attacks.
They were instructed to return to the clinic for the end study visit
upon completion of the treatment of three headaches or if they had
adverse events necessitating withdrawal from the study or if they
wished to withdraw from the study for other reasons.
Patients were encouraged to initiate treatment with the study
medication as early as possible in the migraine regardless of pain
severity or duration of the attack. Forty-three patients were
enrolled. They were provided diaries to record information on
their treated migraine attacks. Among the information gathered in
the diaries were symptoms of cutaneous allodynia recorded by the
patients at 15, 30, 45 min, and 1, 1.5, 2, 3 and 4 h. The symptoms
collected to describe cutaneous allodynia included discomfort
associated with: wearing a necklace or closed neck shirt and tie,
wearing a ring or bracelet, wearing glasses or earrings, taking a
shower, shaving or applying makeup, brushing or combing hair.
The amount of discomfort caused by the allodynic symptoms were
rated using a 1–4 scale (where 1 is mild discomfort, 2 – mild-to-
moderate discomfort, 3 – moderate and 4 – severe discomfort).
A final diary entry was made 24 h from the onset of treatment.
The primary efficacy endpoint was the percentage of patients
achieving relief from headache at 2 h. Relief was defined as
reduction of the pain severity from mild, moderate or severe pain
to none, or from moderate or severe pain to mild pain.
Based on the demographics of the study subjects, correla-
tions were made between the occurrence of cutaneous allodynia
and migraine.
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The study was conducted in accordance with the Good
Clinical Practice procedures, the Declaration of Helsinki, and
the US code of federal regulations concerning informed patient
consent. Patients meeting all of the enrolment criteria were pro-
vided with a written informed consent approved by a nationwide
independent institutional review board.
Results
Of the 50 patients providing informed consent, 43 patients
took at least one dose of study medication. Four patients
terminated the study before treating all three headaches.
One discontinued secondary to multiple adverse events,
and three withdrew consent for other reasons. Additionally,
one patient had unreliable data, which was not included in
the data analysis, and one patient withdrew due to SAEs
without using study medication and provided no outcome
data. Five patients failed to treat any attacks.
The subjects, who were almost exclusively Caucasian
females, had an age range from 25 to 56 years, with a
mean age of 43 years, similar to other migraine trials. All
the patients had a long history of migraine headaches,
ranging from seven to 43 years with a mean of 21.7 years.
The primary efficacy endpoint was the percentage of
patients achieving relief from their headache at 2 h after
using 6 mg SC sumatriptan (Table 1). Thirty-nine of 43
(91%) patients treating the first headache achieved relief
of their headache at 2 h. Similar results were found for the
second and third attacks treated. Eighty-two percent (35
patients) of the second attacks were relieved by 2 h and
72% (31 patients) of the third attacks had also responded
by the 2-h endpoint.
Forty of the 43 patients (93%) had at least one attack
with at least one allodynic symptom at baseline. The mean
number of allodynic symptoms per attack was 2.7.
Approximately 50% of all treated headache attacks
produced pain-free outcomes by 2 h. Additionally, over
30% of all attacks resulted in a 24-h sustained pain-free
response. Migraine-associated symptoms declined from
baseline in a similar pattern to the response of the
headache intensity.
While over one-half of the patients experienced
adverse events, chest symptoms and injection site reac-
tions occurred in only about one-fourth of all patients.
As had been suggested in previous studies, as patients
age they are more likely to have allodynic symptoms. We
found that there was a slow gradual trend with age being
somewhat more likely to increase the likelihood develop-
ment of allodynia (Fig. 1). Similarly, we found that the
number of years that an individual experienced migraine
correlated with an increased likelihood of the individual
developing allodynic symptoms (Fig. 2). The impact of
duration of migraine may have been greater than the effect
Table 1 Response parameters by headache treated
Parameters First headache Second headache Third headache
2-h headache relief 39 (91%) 35 (82%) 31 (72%)
2-h pain-free 24 (56%) 21 (49%) 22 (51%)
24-h sustained pain-free 14 (32%) 14 (32%) 15 (35%)
Mean time to response (min) 56 62 53
Mean time from headache onset to treatment 93 89 82
Fig. 1 Relationship between age and allodynic symptoms
Fig. 2 Relationship between years of migraine and allodynic
symptoms
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of the patient’s age on the development of allodynia.
Baseline headache severity did not correlate with allody-
nia (Table 2).
The headache response was independent of the number
of allodynic symptoms the patient experienced at baseline
(Fig. 3). The vast majority of patients who were allodynic
at baseline were pain-free by 2 h. However, in nine of the
treated attacks that were free of allodynia at baseline,
patients failed to achieve a pain-free response by 2 h.
We examined the symptoms of cutaneous allodynia
reported by patients associated with their headaches. When
both the number that reported allodynic symptoms and their
Table 2 Baseline headache severity allodynia (occurrence and mean number of symptoms per attack)
Baseline headache Total Number with Total number Mean number 
severity number allodynia of allodynic of allodynic symptoms 
symptoms per attack
1 9 8 22 2.5
2 75 55 157 2.09
3 40 40 160 4.0
Table 3 Change in headache pain and allodynia symptoms
Time point/relative change Relative change in allodynia (% of patients)
in headache pain
↓ No change ↑
15 min
Decreased pain 15 11 0
No change in pain 24 50 10
Increased pain 0 4 8
30 min
Decreased pain 38 19 2
No change in pain 24 28 7
Increased pain 0 1 4
1 h
Decreased pain 76 29 1
No change in pain 4 7 3
Increased pain 1 1 1
2 h
Decreased pain 83 25 3
No change in pain 4 6 2
Increased pain 0 0 0
Fig. 3 Two-hour pain-free status and number of allo-
dynic symptoms at baseline
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relative intensity are considered and correlated with the
change in the headache severity (Table 3), we found that the
pain of migraine began to decline prior to the decline in
allodynia. During the first 15–30 min after treatment, allo-
dynia may increase despite decreasing migraine pain.
Seventy-two of the 123 treated attacks led to a pain-
free outcome at 2 h. Of those 72 attacks, 28% of the time
the patient was allodynia-free at baseline. By 2 h, 92% of
the patients had become allodynia-free. That means, how-
ever, that in 72% of the attacks the patient already had
developed allodynic symptoms at baseline and was still
able to achieve a pain-free outcome by 2 h. Only 8% of
the pain-free patients at 2 h maintained allodynic symp-
toms. With an oral triptan, once a patient has become allo-
dynic, we would expect the patient to merely improve but
not achieve a pain-free outcome. Of those patients who
obtained partial relief of their migraine at 2 h, 85% had
allodynia at baseline. For these patients nearly half con-
tinued to experience allodynia at 2 h.
Discussion
In a group of patients who historically had failed to
respond to oral triptans, 6 mg SC sumatriptan proved to be
highly efficacious and well tolerated. Approximately 80%
of these patients responded to a single dose of 6 mg SC
sumatriptan. Roughly half of the patients were pain-free
by 2 h, with approximately a third of the patients having a
24-h sustained pain-free response. The mean time to
response was one hour. The efficacy results were consis-
tent across all three treated headaches.
Migraine-associated symptoms declined in a similar
fashion to the pain. The percentage of patients with reso-
lution of the migraine-associated symptoms ranged
between 50% and 70%, consistently across the three
attacks. Half of the patients experienced adverse events
with about 1.8 adverse events per patient; only one patient
withdrew from the study because of adverse events direct-
ly related to the study medications.
In this group of patients who lacked consistency in
response to oral triptans, we found a consistent response
to the study medication with over 2/3 of patients respond-
ing to all three treated headaches.
Previous studies by Burstein et al. [11, 12] have sug-
gested that when allodynia is measured with sensory test-
ing (QST) the presence of allodynia diminishes the abili-
ty to become pain-free with triptans. The use of QST to
examine cutaneous allodynia is important for our under-
standing of migraine and its treatment.
Burstein’s work has also suggested that factors such as
age, numbers of years with migraine and migraine severi-
ty also influence the development of cutaneous allodynia
in an individual. This population of migraine patients
tended to verify several concepts that have previously
been suggested. That is that both the ageing migraine suf-
ferer as well the patient who has experienced migraine
over more years are both more likely to have symptoms of
cutaneous allodynia than their younger, more briefly
afflicted, counterparts are.
Fifty-eight percent of 124 evaluable headaches pro-
duced a pain-free response by 2 h. Of these, 52 attacks, or
72% of the pain-free attacks, were associated with allody-
nia at baseline. By 2 h however, only 8% of these attacks
still had persisting allodynia. These results would seem to
provide a level of contradiction to the previous work by
Burstein. This contradiction may exist for any one of sev-
eral reasons given the nature of the study.
Similar results were also achieved in a study conduct-
ed by Linde et al. [15].
One of the major difficulties in a study such as this is
the design of the questionnaire. At the time of the study, a
clinical questionnaire to correlate patient-related symp-
toms of allodynia to the laboratory-verified QST findings
of allodynia did not exist. The availability of such a tool
now would improve the reliability of the data obtained in
a similar study.
Seventy-two percent of the aborted attacks were clas-
sified allodynic at the time of treatment. These findings
could be interpreted in several ways: (1) it may suggest
that allodynia is an all-or-none phenomenon and, as such,
the presence of allodynia does not interfere with the abil-
ity to abort the pain by SC sumatriptan; (2) it may suggest
that early allodynia (i.e., developing phase) differs mech-
anistically from late allodynia (established phase) and that
allodynic attacks were aborted because treatment was
issued during the developing, rather than the established,
phase of allodynia and central sensitisation. According to
Burstein et al., the developing phase of allodynia (which
lasts 20–120 min after onset of migraine) is mediated by
an activity-dependent central sensitisation whereas the
established phase of allodynia (which starts about 4 h after
onset of migraine) is mediated by an activity-independent
central sensitisation. In view of the second interpretation,
one would propose that 50% of the patients, although allo-
dynic at the time of treatment, were only at the develop-
ing phase whereas the other 50% had already reached the
established phase of allodynia. Since the time for treat-
ment was within 90 min in the majority of patients, we
cannot favour one of these two options over the other.
Only a study in which treatment is initiated no earlier than
4 h after onset of migraine, using a verified tool for recog-
nising allodynia in the clinic, and studying subjects who
report themselves to be allodynic, will be able to distin-
guish between these options.
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In conclusion, in a population of patients who have
historically failed to respond to oral triptans, sumatriptan
6 mg SC injection proved to be effective and capable of
producing a pain-free response in over 50% of patients
despite the occurrence of allodynic symptoms at baseline
and moderate or severe pain. We found evidence in this
population that the number of symptoms of cutaneous
allodynia increased with increasing age and the number
of years that an individual suffered from migraine
attacks. The response of the patients to resolution of their
migraine headache pain and resolution of allodynic
symptoms, while tending to occur in a simultaneous fash-
ion, could in fact have resolution of migraine headache
pain in advance of resolution of cutaneous allodynia
reduction.
The use of an alternative approach to treatment of
migraine with a more highly reliable delivery such as the
SC delivery of the sumatriptan should be considered in
those patients who have had a history of inconsistent or
non-response to migraine specific treatments.
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